- Breaking News Japan welcomes reelection of Karzai as Afghan president, vows support
- Breaking News U.S. editorial excerpts -2-
- Breaking News 3RD LD: Blast in Pakistan's Rawalpindi kills at least 30
- Breaking News Obama reaffirms support for Karzai as run-off is cancelled
Trading Alert for Achillion Pharmaceuticals, Inc.
0 Comments | M2 Presswire, February, 2007
M2 PRESSWIRE-12 February 2007-bellwetherreport.com: Trading Alert for Achillion Pharmaceuticals, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:12022007 Achillion Pharmaceuticals develops biopharmaceutical treatments for infectious diseases. Drugs in its pipeline include antiviral treatments for HIV infection and hepatitis C, as well as antibacterial treatments for drug-resistant hospital-based bacterial infections.
Lead candidate elvucitabine is in Phase II trials for the treatment of HIV; the drug is designed specifically for patients who have become resistant to existing antiviral drugs. Achillion is working in collaboration with biotech firm Gilead Sciences to develop ACH-806, a possible treatment for chronic hepatitis C. Achillion was founded in 2000....
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Portfolio forecasting tools: what you need to know
- Empirically assessing the impact of BPR on banking firms
- Kemarie McMinn Named Executive Vice President of Halo Debt Solutions, Inc.
- Halo Debt Solutions, Inc. Supports Push Toward Industry Regulation
- Traction Named #1 Interactive Agency for 2009 by BtoB Magazine
- Halo Debt Solutions, Inc. Gives Debt Settlement a Face-Lift
- Banking technology, technological learning and competition: comparative case studies in Thai banking